vyepti
h. lundbeck a/s - eptinezumab - tulburări ale migrenei - analgezice - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
vyepti 100 mg
h. lundbeck a/s - danemarca - eptinezumabum - conc. pt. sol. perf. - 100mg/ml - antimigrenoase analgezice
hemlibra
roche registration limited - emicizumab - hemofilia a - hemostatice - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra poate fi folosit în toate grupele de vârstă.
hemlibra 105 mg/0,7 ml soluţie injectabilă
f.hoffmann-la roche, ltd. - emicizumabum - soluţie injectabilă - 105 mg/0,7 ml
hemlibra 150 mg/1 ml soluţie injectabilă
f.hoffmann-la roche, ltd. - emicizumabum - soluţie injectabilă - 150 mg/1 ml
hemlibra 30 mg/1 ml soluţie injectabilă
f.hoffmann-la roche, ltd. - emicizumabum - soluţie injectabilă - 30 mg/1 ml
hemlibra 60 mg/0,4 ml soluţie injectabilă
f.hoffmann-la roche, ltd. - emicizumabum - soluţie injectabilă - 60 mg/0,4 ml
raylumis
pfizer europe ma eeig - tanezumab - osteoarthritis; pain - analgezice - treatment of moderate to severe chronic pain associated with osteoarthritis (oa) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (nsaids) and/or any opioid is ineffective, not tolerated or inappropriate.
hemlibra 150 mg/ml
roche austria gmbh - austria - emicizumabum - sol. inj. - 150mg/ml - vitamina k si alte hemostatice alte hemostatice sistemice
hemlibra 30 mg/ml
roche austria gmbh - austria - emicizumabum - sol. inj. - 30mg/ml - vitamina k si alte hemostatice alte hemostatice sistemice